Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study
China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the...
Boston Scientific Completes First Surgery with RotaPro in China
US-based Boston Scientific Corporation (NYSE: BSX) has announced the completion of the first surgery using...
Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for...
Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement...
HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a...
Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293
Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI...
Moderna’s CMO Expresses Eagerness to Bring mRNA Vaccines to China
The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been...
Novartis Faces Setback in US Patent Battle Over Multiple Sclerosis Drug Gilenya
Swiss pharmaceutical giant Novartis AG (SWX: NOVN) has encountered its latest and potentially final setback...
Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing...
Hengrui Medicine’s Dexmedetomidine Nasal Spray Gains Priority Review
China’s Center for Drug Evaluation (CDE) has indicated that Hengrui Medicine Co., Ltd’s (SHA: 600276)...
Menarini and OrigiMed Partner on Pan-Cancer Single-Cell Diagnostic Platform
Italy’s Menarini Group has formed a strategic partnership with China-based precision medicine firm OrigiMed to...
Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions
Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is...
InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade
China-based InnoCare Pharma (HKG: 9969) has completed an initial public offering (IPO) of 265 million...
Humanwell’s Generic Clobazam Approved for Lennox-Gastaut Syndrome in China
China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version of Sanofi’s clobazam (trade name: Frisium) has...
AIM Vaccine Plans IPO to Fund Vaccine R&D and Pipeline Expansion
China-based AIM Vaccine Co., Ltd plans to make an initial public offering (IPO) of 9.71...
AstraZeneca and Merck’s Lynparza Receives New Approval in China
UK-based AstraZeneca (NASDAQ: AZN) and US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) have announced...
Shandong Luoxin Partners with Shanghai Pharma for Strategic Services
China-based Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793) has announced a partnership with...
NHSA Releases Guide on Volume-Based Procurement Drug Equivalents
The National Healthcare Security Administration (NHSA) has reportedly released a reference guide for industry players,...
Zelgen Biopharmaceuticals Gains NMPA Approval for Jacktinib Clinical Trial in SLE
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review
UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...